OTCMKTS:CSLLY CSL (CSLLY) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free CSLLY Stock Alerts $91.05 +1.91 (+2.14%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$89.53▼$91.1750-Day Range$86.82▼$94.2952-Week Range$71.51▼$105.11Volume23,909 shsAverage Volume37,280 shsMarket Capitalization$88.00 billionP/E RatioN/ADividend Yield1.20%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get CSL alerts: Email Address CSL MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.42Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth13.97%From $3.15 to $3.59 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.30 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for CSL. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of CSL have been sold short.Short Interest Ratio / Days to CoverCSL has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CSL has recently decreased by 33.72%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend YieldCSL pays a meaningful dividend of 1.22%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthCSL does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, CSL will have a dividend payout ratio of 30.36% next year. This indicates that CSL will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSLLY. Previous Next 1.9 News and Social Media Coverage News SentimentCSL has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CSL this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CSL insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.03% of the stock of CSL is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CSL are expected to grow by 13.97% in the coming year, from $3.15 to $3.59 per share.Price to Book Value per Share RatioCSL has a P/B Ratio of 4.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About CSL Stock (OTCMKTS:CSLLY)CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Read More CSLLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSLLY Stock News HeadlinesApril 3, 2024 | marketbeat.comAkebia Therapeutics Surges on FDA Approval for Anemia Treatment (CSLLY)Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemiaMay 2, 2024 | markets.businessinsider.comCSL : Real-World Evidence Study Proves Effectiveness Of Cell-Based Quadrivalent Influenza VaccinesMay 2, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” May 2, 2024 | prnewswire.comRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three SeasonsApril 28, 2024 | msn.comHere is the dividend forecast to 2028 for CSL sharesApril 25, 2024 | investorplace.comCSL Stock Earnings: Carlisle Companies Beats EPS, Beats Revenue for Q1 2024April 24, 2024 | prnewswire.comCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 16, 2024 | msn.comHow much do you need to invest in CSL shares for $8,000 in annual dividends?May 2, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 12, 2024 | markets.businessinsider.comUBS Sticks to Their Buy Rating for CSL (CMXHF)April 9, 2024 | afr.comMacquarie brokers say CSL is heading to $500 per shareApril 5, 2024 | investorplace.comCSLR Stock Earnings: Complete Solaria Beats EPS, Misses Revenue for Q4 2023April 2, 2024 | fool.com.auOwn CSL shares? You're receiving a healthy dividend boost today!March 28, 2024 | finance.yahoo.comVafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patientsMarch 26, 2024 | afr.comBlood giant CSL works up $US1 billion-plus bond deal; banks mandatedMarch 11, 2024 | finance.yahoo.comCSL Ltd's Dividend AnalysisMarch 6, 2024 | prnewswire.comCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. SeasonFebruary 15, 2024 | markets.businessinsider.comWilsons downgrades CSL (CMXHF) to a HoldFebruary 13, 2024 | fool.com.auCSL shares tumble despite first-half earnings beatFebruary 13, 2024 | afr.comWhat we learnt from CSL, Challenger, Seek and Breville’s resultsFebruary 13, 2024 | finanznachrichten.deCSL Limited: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³February 12, 2024 | fool.com.auCSL share price on watch amid 20% profit jumpFebruary 12, 2024 | marketwatch.comCSL Says 1H Profit Rises, Boosts Dividend -- UpdateFebruary 12, 2024 | afr.comCSL shrugs off trial setback to post double-digit earnings growthFebruary 12, 2024 | wsj.comCSL Profit Rises, Boosts DividendFebruary 12, 2024 | msn.comCSL Limited falls after Phase 3 setback for key trialFebruary 12, 2024 | msn.comAsian stocks move little in holiday-thinned trade; CSL drags on AustraliaSee More Headlines Receive CSLLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CSLLY CUSIPN/A CIK1274152 Webwww.csl.com.au Phone(139) 389-1911Fax61-3-9389-1434Employees32,000Year Founded1904Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$13.31 billion Price / Sales6.47 Cash Flow$3.12 per share Price / Cash Flow28.58 Book Value$18.48 per share Price / Book4.82Miscellaneous Outstanding Shares966,510,000Free FloatN/AMarket Cap$86.15 billion OptionableNot Optionable Beta0.74 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Paul F. McKenzie Ph.D. (Age 58)MD, CEO & Executive Director Comp: $2.75MMs. Joy Carolyn Linton B.Com. (Age 59)BComm, GAICD, Grad Dip AFI, Chief Financial Officer Comp: $2.05MMr. Mark DehringHead of Investor RelationsMr. Gregory Boss B.S. (Age 63)BS(Hons), J.D., Executive VP of Legal & General Counsel Comp: $1.1MChristina HickieSenior Manager of CommunicationsMs. Roanne ParryChief Human Resources OfficerDr. Karen Etchberger (Age 66)Executive Vice President of Quality & Business Services Comp: $1.03MMs. Jemimah BrennanHead of Communications - Asia PacificDr. Andrew D. Nash BSc (Hons) (Age 62)GAICD, Ph.D., Senior Vice President of Research Dr. William Mezzanotte M.D. (Age 65)M.P.H., Executive VP & Head of Research and Development Comp: $1.46MMore ExecutivesKey CompetitorsGSKNYSE:GSKBristol-Myers SquibbNYSE:BMYRegeneron PharmaceuticalsNASDAQ:REGNZoetisNYSE:ZTSVertex PharmaceuticalsNASDAQ:VRTXView All Competitors Should I Buy CSL Stock? CSLLY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in CSL Limited: CSL Limited operates in the pharmaceutical preparations industry, which is known for its stability and potential for growth. CSL Limited has a diverse product portfolio, including plasma products, gene therapies, and vaccines, which can provide revenue streams from various sources. Recent developments have shown CSL Limited's commitment to research and development, ensuring a pipeline of innovative products for the future. CSL Limited's stock price has shown resilience and potential for growth, with a recent price of $97.17 on record date 12/31/2023. CSL Limited has a global presence, operating in multiple countries, which can help mitigate risks associated with regional economic fluctuations. Cons Investors should be bearish about investing in CSL Limited for these reasons: CSL Limited's outstanding shares information is not available, which may indicate limited transparency into the company's ownership structure. CSL Limited's institutional ownership percentage is currently at 0, which may raise concerns about institutional confidence in the company. CSL Limited's short percentage of float is 0, which may indicate limited interest from short-term investors in the company's stock. CSL Limited's month-to-month change percentage in shares shorted was -0.2638, which may suggest a bearish sentiment among some investors. CSL Limited's float size is 0, which may raise questions about the liquidity of the company's shares in the market. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these CSL pros and cons to contact@marketbeat.com. CSLLY Stock Analysis - Frequently Asked Questions How have CSLLY shares performed in 2024? CSL's stock was trading at $97.17 on January 1st, 2024. Since then, CSLLY shares have decreased by 6.3% and is now trading at $91.05. View the best growth stocks for 2024 here. Are investors shorting CSL? CSL saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 5,700 shares, a drop of 33.7% from the March 31st total of 8,600 shares. Based on an average trading volume of 57,300 shares, the days-to-cover ratio is currently 0.1 days. View CSL's Short Interest. Is CSL a good dividend stock? CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.09 per share and currently has a dividend yield of 1.22%. Read our dividend analysis for CSLLY. How do I buy shares of CSL? Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CSLLY) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CSL Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.